Sort   by:  
 Page size 
UnknownOutcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
Not available
S-EPMC9700253 | biostudies-literature
UnknownDaratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Not available
S-EPMC7332897 | biostudies-literature
UnknownEarlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Not available
S-EPMC9293158 | biostudies-literature
UnknownPatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Not available
S-EPMC12321245 | biostudies-literature
UnknownNK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.
Not available
S-EPMC10155898 | biostudies-literature
UnknownA randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study.
Not available
S-EPMC7596850 | biostudies-literature
UnknownKTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Not available
S-EPMC11613962 | biostudies-literature
UnknownBiomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia.
Not available
S-EPMC11006814 | biostudies-literature
Sort   by:  
 Page size